Latest News

Chengdu, China – HBV-related hepatocellular carcinoma poses a significant global health challenge, characterized by its cellular diversity and complex tumor immune microenvironment. The increasing unmet need in HBV-HCC treatment drives to deeper understand the role of the intricate immune microenvironment, tumor cell plasticity and dynamics of tumor evolution in HBV-associated...
SAN DIEGO ― Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations. Results from the studies were shared today in oral presentations at the...
Tsukuba, Japan – Type 2 diabetes, a prominent form of diabetes, is widely recognized for its association with insulin resistance—a condition wherein insulin becomes ineffective. This ineffectiveness stems from factors such as obesity, disruption of compensatory insulin secretion by pancreatic beta cells (pancreatic beta cell dysfunction), and a decrease in...
Vienna, Austria – Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even eliminate the need for insulin therapy.1 This innovative approach, which combines a novel procedure known as ReCET (Re-Cellularization via Electroporation Therapy) with...
WEST LAFAYETTE, Ind. — Purdue University researchers are developing and validating a patent-pending treatment for incurable glioblastoma brain tumors. Glioblastomas are almost always lethal with a median survival time of 14 months. Traditional methods used against other cancers, like chemotherapy and immunotherapy, are often ineffective on glioblastoma. Sandro Matosevic, associate...